Phillip P. Chan

Dr. Phillip Chan is the Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO). Over the past 12 years, Dr. Chan has led the company through the E.U. approval and commercialization of its flagship product, CytoSorb, as a novel blood purification therapy to treat cytokine storms and control deadly inflammation seen in life-threatening illnesses in the intensive care unit and cardiac surgery. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as a Partner for the $80M NJTC Venture Fund, one of the largest seed and Series A early-stage venture investors in the greater New York region, and a top 1% performing fund for its vintage. Dr. Chan is also a co-founder and Vice-Chairman of Medality Medical, fka Andrew Technologies, a privately-held medical device company pursuing a surgical cure of Type 2 diabetes through the removal of deep mesenteric metabolic fat with its FDA-approved HydraSolve™ advanced lipoplasty system. Dr. Chan received Board-certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. He received his MD/Ph.D. from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University.